Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.63−0.33 (-4.74%)
Close on Nov 16, 2026Market cap $437.91MP/E –Yield –
Evolus r&d expenses
Research and development expenses are spending on new products and technology.
Evolus's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.66M, up 9.8% year over year. For fiscal 2025 it was $9.58M, up 4.4% from the year before. The highest annual figure on record is $9.58M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.58M | +4.4% |
| FY2024 | Dec 31, 2024 | $9.17M | +39.9% |
| FY2023 | Dec 31, 2023 | $6.56M | +38.3% |
| FY2022 | Dec 31, 2022 | $4.74M | +129.7% |
| FY2021 | Dec 31, 2021 | $2.06M | +19.9% |
| FY2020 | Dec 31, 2020 | $1.72M | -56.7% |
| FY2019 | Dec 31, 2019 | $3.97M | -38.8% |
| FY2018 | Dec 31, 2018 | $6.49M | -3.0% |
| FY2017 | Dec 31, 2017 | $6.69M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.89M | +3.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.24M | +1.3% |
| Q4 FY2025 | Dec 31, 2025 | $3.48M | +43.3% |
| Q3 FY2025 | Sep 30, 2025 | $2.05M | -11.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.84M | -21.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.21M | +6.4% |
| Q4 FY2024 | Dec 31, 2024 | $2.43M | +2.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.31M | +45.8% |
| Q2 FY2024 | Jun 30, 2024 | $2.35M | +94.5% |
| Q1 FY2024 | Mar 31, 2024 | $2.08M | +50.5% |
| Q4 FY2023 | Dec 31, 2023 | $2.38M | +76.6% |
| Q3 FY2023 | Sep 30, 2023 | $1.59M | +15.3% |
| Q2 FY2023 | Jun 30, 2023 | $1.21M | -22.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.38M | +195.1% |
| Q4 FY2022 | Dec 31, 2022 | $1.35M | +218.7% |
| Q3 FY2022 | Sep 30, 2022 | $1.38M | +357.1% |
| Q2 FY2022 | Jun 30, 2022 | $1.55M | +210.6% |
| Q1 FY2022 | Mar 31, 2022 | $468.00K | -44.4% |
| Q4 FY2021 | Dec 31, 2021 | $423.00K | -41.2% |
| Q3 FY2021 | Sep 30, 2021 | $301.00K | -14.0% |
| Q2 FY2021 | Jun 30, 2021 | $499.00K | +244.1% |
| Q1 FY2021 | Mar 31, 2021 | $841.00K | +65.9% |
| Q4 FY2020 | Dec 31, 2020 | $719.00K | +72.0% |
| Q3 FY2020 | Sep 30, 2020 | $350.00K | -49.5% |
| Q2 FY2020 | Jun 30, 2020 | $145.00K | -71.5% |
| Q1 FY2020 | Mar 31, 2020 | $507.00K | -78.5% |
| Q4 FY2019 | Dec 31, 2019 | $418.00K | -64.7% |
| Q3 FY2019 | Sep 30, 2019 | $693.00K | -64.9% |
| Q2 FY2019 | Jun 30, 2019 | $509.00K | -69.1% |
| Q1 FY2019 | Mar 31, 2019 | $2.35M | +40.2% |
| Q4 FY2018 | Dec 31, 2018 | $1.18M | -2.0% |
| Q3 FY2018 | Sep 30, 2018 | $1.98M | +34.9% |
| Q2 FY2018 | Jun 30, 2018 | $1.65M | +20.7% |
| Q1 FY2018 | Mar 31, 2018 | $1.68M | -36.7% |
| Q4 FY2017 | Dec 31, 2017 | $1.21M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.47M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.37M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.65M | – |
See a number that looks wrong?